var data={"title":"Echothiophate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Echothiophate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6088?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=echothiophate-drug-information\" class=\"drug drug_general\">see &quot;Echothiophate: Drug information&quot;</a> and <a href=\"topic.htm?path=echothiophate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Echothiophate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164017\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Phospholine Iodide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010366\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Ophthalmic Agent, Antiglaucoma</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Ophthalmic Agent, Miotic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010383\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=echothiophate-drug-information\" class=\"drug drug_general\">see &quot;Echothiophate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric: <b>Esotropia, accommodative:</b> Children and Adolescents: Ophthalmic: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diagnosis: Instill 1 drop (0.125%) once daily into both eyes at bedtime for 2 to 3 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment: Instill 1 drop (0.06%) once daily in both eyes or 1 drop (0.125%) every other day in both eyes; gradually lower dose as treatment progresses. Maximum daily dose: 1 drop (0.125%) once daily in both eyes. <b>Note:</b> Use lowest concentration and frequency which gives satisfactory response; if necessary, doses using &gt;0.125% daily may be used for short periods of time. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult: <b>Glaucoma:</b> Ophthalmic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Initial: Instill 1 drop (0.03%) twice daily into eyes with 1 dose just prior to bedtime </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maintenance: Twice-daily dosing is preferred but some patients have been treated with once-daily or every-other-day dosing (with 1 dose just prior to bedtime)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Conversion from other ophthalmic agents: If IOP control was unsatisfactory, patients may be expected to require higher doses of echothiophate (eg, &ge;0.06%); however, patients should be initially started on the 0.03% strength for a short period to better tolerate higher strengths.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal Impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic Impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164005\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Ophthalmic: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Phospholine Iodide: 0.125% (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163992\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46077456\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Proper administration technique is required for maximal benefit. Wash hands prior to use; to avoid contamination, do not allow dispenser tip to touch the eye or any surface; apply gentle pressure to the nasolacrimal duct(s) for 1 to 2 minutes after instillation of the drops to minimize drainage into nose and throat. Excess fluid around the eye should be blotted with tissue; wash hands after instillation. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164016\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store undiluted vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Store reconstituted solutions at ~25&deg;C (~77&deg;F); do not refrigerate; discard unused solution after 4 weeks. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010367\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Diagnosis and treatment of accommodative esotropia (FDA approved in pediatric patients [age not specified]); treatment of chronic open-angle glaucoma; subacute or chronic angle-closure glaucoma (postiridectomy or where surgery is refused or contraindicated); certain nonuveitic secondary types of glaucoma, especially glaucoma following cataract surgery (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164030\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, cardiac abnormality, flushing, hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Brow ache, myasthenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blepharospasm, blurred vision, burning sensation of eyes, cataract, conjunctival abnormalities (thickening), conjunctival erythema, eye redness, increased intraocular pressure (paradoxical), iris cyst, iritis (latent), lacrimal duct obstruction (nasolacrimal canal), lacrimation, miosis, myopia, retinal detachment, stinging of eyes, uveitis (activation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164010\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to echothiophate or any component of the formulation; most cases of angle-closure glaucoma; active uveal inflammation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163996\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac irregularities: Temporarily or permanently discontinue if cardiac irregularities occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholinergic effects: Discontinue if symptoms of excess cholinergic activity (eg, salivation, sweating, urinary incontinence); overdosage may result in cholinergic crisis, which must be distinguished from myasthenic crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Not generally recommended for use in patients with asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Not generally recommended for use in patients with bradycardia, hypotension or recent MI. In a scientific statement from the American Heart Association, ophthalmic cholinergic agents have been determined to be agents that may exacerbate underlying myocardial dysfunction (magnitude: minor) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Not generally recommended for use in patients with spastic gastrointestinal disturbances or  peptic ulcer disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinsonism: Not generally recommended for use in patients with Parkinsonism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Not generally recommended for use in patients with a history of seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vagotonia: Not generally recommended for use in patients with vagotonia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not use for tonometric glaucoma, or in patients with active or history of uveitis, or history of retinal detachment. Use cautiously prior to ophthalmic surgery due to risk of blood in the anterior chamber. Compress the nasolacrimal ducts for 1 to 2 minutes following instillation to minimize drainage into the nasal chamber. Wash hands following instillation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Exposure to pesticides and insecticides: Use with caution in patients exposed to carbamate- or organophosphate-type insecticides and pesticides; absorption of the pesticide through skin or respiratory tract may result in  additive systemic effects; respiratory masks and frequent clothing changes may be necessary during exposure to pesticides in patients receiving echothiophate iodide.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tolerance: Patients may develop tolerance after prolonged use; a rest period restores response to the drug.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299249\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3017787\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=106576&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Cyclopentolate: May diminish the therapeutic effect of Echothiophate Iodide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mivacurium: Echothiophate Iodide may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: Echothiophate Iodide may increase the serum concentration of Succinylcholine.  Management: For patients receiving echothiophate iodide eye drops, consider using a neuromuscular-blocking agents other than succinylcholine. If succinylcholine is used, consider a reduced dose, and monitor for enhanced/prolonged effects.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164001\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3017784\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Animal reproduction studies have not been conducted. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46077457\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Baseline measurement of anterior chamber angle; routine lens examinations (for opacities and during treatment of accommodative esotropia); IOP (at different times of the day)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163995\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Long-acting inhibition of cholinesterase enhances activity of endogenous acetylcholine. Reduced degradation of acetylcholine leads to continuous stimulation of  the ciliary muscle producing miosis; other effects include potentiation of accommodation and facilitation of aqueous humor outflow, with attendant reduction in intraocular pressure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164009\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Miosis: &le;60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Intraocular pressure decrease: After 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Miosis: 1 to 4 weeks; Intraocular pressure: Days to weeks. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164012\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Phospholine Iodide Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125% (5 mL): $106.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038607\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Phospholine Iodide (BB, IL);</li>\n      <li>Phospholine Jodide (HN);</li>\n      <li>Phospholinjodid (AT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abrahamson IA Jr, Abrahamson IA Sr. Prelimary report on 0.06-percent phospholine (echothiophate) iodide in the management of esotropia. <i>Am J Ophthalmol</i>. 1964;57:290-298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/echothiophate-pediatric-drug-information/abstract-text/14123459 /pubmed\" target=\"_blank\" id=\"14123459 \">14123459 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Birks DA, Prior VJ, Silk E, Whittaker M. Echothiophate iodide treatment of glaucoma in pregnancy. <i>Arch Ophthalmol</i>. 1968;79(3):283-285.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/echothiophate-pediatric-drug-information/abstract-text/5640850 /pubmed\" target=\"_blank\" id=\"5640850 \">5640850 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phospholine iodide (echothiophate iodide) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; April 2010.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 106576 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F164017\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1010366\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1010383\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F164005\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F163992\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46077456\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F164016\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1010367\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F164030\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F164010\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F163996\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299249\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F3017787\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F164001\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3017784\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46077457\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F163995\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F164009\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F164012\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038607\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/106576|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=echothiophate-drug-information\" class=\"drug drug_general\">Echothiophate: Drug information</a></li><li><a href=\"topic.htm?path=echothiophate-patient-drug-information\" class=\"drug drug_patient\">Echothiophate: Patient drug information</a></li></ul></div></div>","javascript":null}